6-aminocarbovir
6-aminocarbovir structure
|
Common Name | 6-aminocarbovir | ||
|---|---|---|---|---|
| CAS Number | 124752-25-6 | Molecular Weight | 246.26800 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C11H14N6O | Melting Point | 180-182°C | |
| MSDS | N/A | Flash Point | N/A | |
| Symbol |
GHS05 |
Signal Word | Danger | |
| Name | (1α,4α)-4-(2,6-Diamino-9H-purin-9-yl)-2-cyclopentenyl-carbinol |
|---|---|
| Synonym | More Synonyms |
| Melting Point | 180-182°C |
|---|---|
| Molecular Formula | C11H14N6O |
| Molecular Weight | 246.26800 |
| Exact Mass | 246.12300 |
| PSA | 115.87000 |
| LogP | 1.26260 |
| Vapour Pressure | 1.21E-16mmHg at 25°C |
| Storage condition | -20?C Freezer |
| Symbol |
GHS05 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H318 |
| Precautionary Statements | P280-P305 + P351 + P338 |
| Hazard Codes | Xi |
| Risk Phrases | 41-43 |
| Safety Phrases | 26-36/37-39 |
| RIDADR | NONH for all modes of transport |
|
~97%
6-aminocarbovir CAS#:124752-25-6 |
| Literature: EMORY UNIVERSITY Patent: WO2009/21114 A1, 2009 ; Location in patent: Page/Page column 44; 47 ; |
|
~98%
6-aminocarbovir CAS#:124752-25-6 |
| Literature: Ando, Takayuki; Iwata, Masafumi; Zulfiqar, Fazila; Miyamoto, Tatsuya; Nakanishi, Masayuki; Kitade, Yukio Bioorganic and Medicinal Chemistry, 2008 , vol. 16, # 7 p. 3809 - 3815 |
|
~74%
6-aminocarbovir CAS#:124752-25-6 |
| Literature: Vince; Brownell; Beers Nucleosides and Nucleotides, 1995 , vol. 14, # 1-2 p. 39 - 44 |
|
~%
6-aminocarbovir CAS#:124752-25-6 |
| Literature: Nucleosides and Nucleotides, , vol. 14, # 1-2 p. 39 - 44 |
![9-[cis-(1'R,4'S)-4'-acetoxymethyl-2'-cyclopenten-1'-yl]-9H-2-amino-6-chloropurine structure](https://image.chemsrc.com/caspic/108/162992-44-1.png)
| Precursor 3 | |
|---|---|
| DownStream 0 | |
|
Comparative brain exposure to (-)-carbovir after (-)-carbovir or (-)-6-aminocarbovir intravenous infusion in rats.
Pharm. Res. 12(6) , 911-5, (1995) Evaluate the ability of (-)-6-aminocarbovir ((-)-6AC) to improve the CNS exposure to (-)-carbovir ((-)-CBV).Activation of (-)-6AC in vitro was assessed by incubations of rat brain tissue homogenates. ... |
|
|
Pharmacokinetic evaluation of (-)-6-aminocarbovir as a prodrug for (-)-carbovir in rats.
Drug Metab. Dispos. 20(1) , 47-51, (1992) The recently synthesized carbocyclic 2',3'-didehydro-2',3'-dideoxy-6-deoxy-6-amino-guanosine [(-)6AC] was evaluated as a prodrug for carbovir, carbocyclic 2',3'-didehydro-2',3'-dideoxyguanosine [(-)CB... |
|
|
First-pass disposition of (-)-6-aminocarbovir in rats. I. Prodrug activation may be limited by access to enzyme.
Drug Metab. Dispos. 27(1) , 113-21, (1999) Several in vitro and in situ approaches were used to determine the dominant presystemic activation site for (-)-6-aminocarbovir, (-)-carbocyclic 2',3'-didehydro-2', 3'-dideoxy-6-deoxy-6-aminoguanosine... |
| ABACAVIR RELATED COMPOUND |
| Descyclopropyl Abacavir |
| Abacavir Impurity 3 |